FDA Updates

Tocilizumab-anoh is expected to increase competition, improve patient access, and deliver cost savings in the treatment of various inflammatory conditions.

The regenerative medicine advanced therapy designation expedites the development and review of regenerative medications that have the potential to address unmet needs for serious or life-threatening diseases.

The approval includes indications for rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19.

Meloxicam and rizatriptan reduces migraine pain and help patients return to normal functioning with efficacy through 24 to 48 hours after a single dose for some patients.

Apitegromab is a muscle-targeted therapy for improvement of motor function in individuals with spinal muscular atrophy.

The supplemental new drug application is based on objective response rate and duration of response results from a phase 2 study that assessed the efficacy and safety of belzutifan.

This marks the first US biologic license application filing acceptance for a biosimilar candidate to golimumab.

This follows the approval of everolimus tablets for patients aged 1 and older in January 2025.

MB-105 is a first-in-class CD5-targeted chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed or refractory CD5-positive T-cell lymphoma.

The new indication for semaglutide adds to the long list of conditions that the GLP-1 receptor agonist has been approved for, and provides a new option for high-risk patients with these chronic conditions.

The antibody-drug conjugate shows efficacy in reducing disease progression risk and increasing progression-free survival in patients with HR+, HER2-low, or HER2-ultralow metastatic breast cancer.

The cobas liat system is a closed system that aims to reduce contamination risks and enhances the reliability of results at the point of care.

Administered every 4 weeks, the approval could serve as a breakthrough for easier and more effective care for patients with early Alzheimer disease.

Based on the updated label, new pharmacodynamic data have been added for a better understanding of the drug for individuals with attention-deficit/hyperactivity disorder (ADHD).

The fast-track designation follows the FDA orphan drug designation that was granted for DYNE-101 in September 2023 for the same treatment population.

The drug is being investigated as a PET diagnostic of cardiac amyloid light-chain and amyloid transthyretin-related (ATTR) amyloidosis.

Memantine/donepezil and everolimus are used to treat dementia of the Alzheimer type and tuberous sclerosis complex-associated subependymal giant cell astrocytoma, respectively.

Patients with multiple sclerosis being treated with glatiramer acetate have an increased risk of experiencing anaphylaxis.

The FDA approved treosulfan, in combination with fludarabine, for patients 1 year of age and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Vusolimogene oderparepvec in combination with nivolumab is being assessed to treat individuals with unresectable or metastatic stage IIIb-IV cutaneous melanoma.

Esketamine targets glutamate, the most abundant neurotransmitters in the brain.

The closure of Baxter’s North Cove facility has significantly impacted existing IV fluid shortages into 2025.

The report from the Office of Inspector General highlights inconsistencies, lack of transparency, and the need for stronger safeguards.

Compared with chemotherapy, Dato-DXd demonstrates favorable median progression-free survival and overall survival in a phase 3 clinical trial.

The FDA proposes to cap the nicotine level at 0.7 mg per gram of tobacco in cigarettes and certain other combusted tobacco products.

If finalized, the requirement would include readily available nutrition information, including saturated fat, sodium, and added sugar content.

Data from the CodeBreaK 300 trial supported the FDA's approval.